# Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients

> **NCT03328884** · PHASE2 · COMPLETED · sponsor: **MedSIR** · enrollment: 55 (actual)

## Conditions studied

- Breast Cancer Metastatic

## Interventions

- **DRUG:** Irinotecan (CPT-11) liposome

## Key facts

- **NCT ID:** NCT03328884
- **Lead sponsor:** MedSIR
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-02
- **Primary completion:** 2018-08-31
- **Final completion:** 2025-04-02
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03328884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03328884, "Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03328884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*